CELG Snaps Up RCPT, PETX Has Its Day, BIOC, RWLK Roll Out Products

(RTTNews) - Shares of Aratana Therapeutics Inc. (PETX) were up more than 7% in after-hours trading on Tuesday, following positive results from its pivotal field effectiveness study of AT-003, the company's innovative drug for treating post-surgical pain in dogs.

AT-003 is an extended-release bupivacaine liposome injectable suspension licensed from Pacira Pharmaceuticals Inc. (PCRX).

Aratana anticipates commencing commercialization of AT-003 for dogs in 2016.

PETX closed Tuesday's trading 1.33% higher at $16.77. In after-hours, the stock was up 7.33% at $18.00.

Biocept Inc. (BIOC) has launched its proprietary, quantitative assay targeting BRAF mutations utilizing a patient's blood sample, which provides physicians with a liquid biopsy option to reach informed treatment decisions for patients with melanoma and other tumors.

The company plans to launch additional biomarkers for melanoma and other solid tumors this year that physicians can use when making treatment decisions.

BIOC closed Tuesday's trading at $2.80, up 6.06%.

Celgene Corp. (CELG) is all set to acquire Receptos Inc. (RCPT) in a deal valued at approximately $7.2 billion, or $232.00 per share, in cash.

According to Celgene, the acquisition significantly enhances its Inflammation & Immunology portfolio, further diversifies its revenue beginning in 2019 and beyond, and builds upon the growing expertise in inflammatory bowel disease.

The transaction is anticipated to close in 2015.

When our Short Term Investor service alerted readers to RCPT last June, the stock was trading around $39. Had you bought the stock then and continued to hold it, you would have made a gain of over 480% now based on the offer price.

ReWalk Robotics Ltd. (RWLK) has launched the latest edition of its FDA-cleared Personal powered exoskeleton system - the ReWalk Personal 6.0 for home and community use.

ReWalk Personal 6.0, which is the company's sixth generation community use product, offers users the fastest walking speed, most natural gait, and the most precise fit of any exoskeleton, according to the company.

RWLK closed Tuesday's trading at $10.19, up 4.84%.